U.S. reclassifies state-licensed medical marijuana
The reclassification aims to ease research barriers and provide tax relief. This change represents a significant shift in U.S. cannabis policy. (sources: science, politico, bloomberg, france24, thehill)
The Trump administration has reclassified state-licensed medical marijuana as a less dangerous drug. This decision could facilitate scientific research and offer tax benefits.
- The reclassification applies to state-licensed medical marijuana.
- The change aims to ease barriers for research and provide tax relief.
- This decision does not equate to federal legalization of cannabis.
Why it matters
This reclassification could influence the future of cannabis research and policy in the United States.
↓ Why this is on ModernAction
3 bills on this issue are moving right now — and the most active one is Marijuana 1-to-3 Act of 2025.
H.R.4963 · 119th Congress
Marijuana 1-to-3 Act of 2025
Where do you stand on this bill?
Takes about 60 seconds
About this bill
What H.R.4963 actually does
This story is about U.S. moves to reclassify some types of marijuana as lower risk. This bill would require marijuana be transferred to Schedule III by statute.
If passed, it would:
- Require marijuana be transferred to Schedule III by statute (rather than only via the administrative process • Set a clear congressional baseline for downstream federal compliance (research, prescribing rules.
2 other bills moving on this issue
Take action on any of them individually.
This story is about U.S. moves to reclassify some types of marijuana as lower risk. This bill would decriminalize and deschedule cannabis under federal law.
If passed, it would
- Decriminalize and deschedule cannabis under federal law • Create mechanisms tied to expungement and reinvestment for people impacted by cannabis prohibition.
This story is about U.S. moves to reclassify some types of marijuana as lower risk. This bill would limit federal CSA penalties for state/tribal-compliant marijuana activity.
If passed, it would
- Limit federal CSA penalties for state/tribal-compliant marijuana activity • Assign federal regulatory roles for marijuana products (including FDA-related authorities) and address issues like.